BioSpace News Archive

Micro-Tech Endoscopy USA, the U.S. subsidiary of the global medical device company Micro-Tech (Nanjing) Co. Ltd, which develops and supplies diagnostic and therapeutic devices in the gastroenterology space, has announced a business partnership with Wision A.I., a startup in the field of artificial intelligence-assisted diagnostics for optical medical imaging.

Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, will present details on its R&D pipeline combining wearable delivery devices with subcutaneous formulation technology.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022.

Freenome, a privately held biotech company, together with the Morehouse School of Medicine, presented findings at the Digestive Disease Week (DDW) annual meeting showing high clinical study enrollment of Black patients using various strategies to reduce participation barriers.

Teva Presents New Long-Term AUSTEDO ® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting.

The Family Heart Foundation, a leading research and advocacy organization, today announced study results that demonstrate individuals with elevated lipoprotein(a) – also referred to as Lp(a) —levels experience an increased rate of cardiovascular events.

Biotricity Inc. is scheduled to present and will be participating in a fireside chat at the H.C. Wainwright Global Investment Conference, being held from May 23-26, 2022.

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio at the 2022 American Society of Clinical Oncology Scientific Program (#ASCO22) and the European Hematology Association Congress (#EHA22).

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803.

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), announced today its participation at the William Blair 42 nd Annual Growth Stock Conference , which takes place June 6-9, 2022.